Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index; 26 of the 48 sources its claims cite were checked for support.
Abstract
BACKGROUND: Ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen (BCMA)-directed CAR T-cell therapy, is effective in heavily pretreated patients with relapsed or refractory multiple myeloma. We investigated cilta-cel in earlier treatment lines in patients with lenalidomide-refractory disease. METHODS: In this phase 3, randomized, open-label trial, we assigned patients with lenalidomide-refractory multiple myeloma to receive cilta-cel or the physician's choice of effective standard care. All the patients had received one to three previous lines of treatment. The primary outcome was progression-free survival. RESULTS: A total of 419 patients underwent randomization (208 to receive cilta-cel and 211 to receive standard care). At a median follow-up of 15.9 months (range, 0.1 to 27.3), the median progression-free survival was not reached in the cilta-cel group and was 11.8 months in the standard-care group (hazard ratio, 0.26; 95% confidence interval [CI], 0.18 to 0.38; P<0.001). Progression-free survival at 12 months was 75.9% (95% CI, 69.4 to 81.1) in the cilta-cel group and 48.6% (95% CI, 41.5 to 55.3) in the standard-care group. More patients in the cilta-cel group than in the standard-care group had an overall response (84.6% vs. 67.3%), a complete response or better (73.1% vs. 21.8%), and an absence of minimal residual disease (60.6% vs. 15.6%). Death from any cause was reported in 39 patients and 46 patients, respectively (hazard ratio, 0.78; 95% CI, 0.5 to 1.2). Most patients reported grade 3 or 4 adverse events during treatment. Among the 176 patients who received cilta-cel in the as-treated population, 134 (76.1%) had cytokine release syndrome (grade 3 or 4, 1.1%; no grade 5), 8 (4.5%) had immune effector cell-associated neurotoxicity syndrome (all grade 1 or 2), 1 had movement and neurocognitive symptoms (grade 1), 16 (9.1%) had cranial nerve palsy (grade 2, 8.0%; grade 3, 1.1%), and 5 (2.8%) had CAR-T-related peripheral neuropathy (grade 1 or 2, 2.3%; grade 3, 0.6%). CONCLUSIONS: A single cilta-cel infusion resulted in a lower risk of disease progression or death than standard care in lenalidomide-refractory patients with multiple myeloma who had received one to three previous therapies. (Funded by Janssen and Legend Biotech; CARTITUDE-4 ClinicalTrials.gov number, NCT04181827.).
Overview
CoChat Summary
TL;DR
In CARTITUDE-4, a single cilta-cel infusion significantly improved progression-free survival versus physician’s choice standard care in lenalidomide-refractory multiple myeloma after one to three prior lines. Cilta-cel also produced higher response and MRD-negativity rates, with mostly manageable CAR-T-specific adverse events.
Key findings
- At a median follow-up of 15.9 months, median progression-free survival was not reached with cilta-cel versus 11.8 months with standard care (HR, 0.26; 95% CI, 0.18 to 0.38; P<0.001); 12-month progression-free survival was 75.9% vs. 48.6%.
- Cilta-cel produced higher overall response (84.6% vs. 67.3%), complete response or better (73.1% vs. 21.8%), and MRD negativity (60.6% vs. 15.6%).
- Overall survival was immature: death from any cause occurred in 39 cilta-cel patients and 46 standard-care patients (HR, 0.78; 95% CI, 0.5 to 1.2; P=0.26); 12-month survival was 84.1% vs. 83.6%.
- Grade 3 or 4 adverse events occurred in 96.6% vs. 94.2%; among 176 as-treated cilta-cel patients, cytokine release syndrome occurred in 76.1% (grade 3 or 4, 1.1%; no grade 5), ICANS in 4.5% (all grade 1 or 2), cranial nerve palsy in 9.1%, and CAR-T-related peripheral neuropathy in 2.8%.
Methods
- Phase 3, randomized, open-label trial at 81 sites in the United States, Europe, Asia, and Australia; 419 patients with lenalidomide-refractory multiple myeloma after one to three prior lines, ECOG performance-status score ≤1, and no prior CAR-T or BCMA-targeted therapy were assigned 1:1 to cilta-cel (208) or standard care (211; PVd or DPd).
- Cilta-cel patients received apheresis, bridging therapy, lymphodepletion, and a single cilta-cel infusion (target dose, 0.75×10^6 CAR+ viable T cells/kg); standard-care patients received DPd or PVd until progression, with no protocol-permitted crossover.
- Primary outcome was progression-free survival; efficacy was analyzed in the intention-to-treat population with Kaplan-Meier estimates, a stratified weighted log-rank test, and stratified Cox regression; adverse events were evaluated in the safety population and CAR-T-specific events in the as-treated population.
Limitations
- Stated: two highly efficacious triplet regimens—daratumumab, carfilzomib, and dexamethasone and isatuximab, carfilzomib, and dexamethasone—were not approved at trial initiation and could not be included as standard-care options.
- Stated: early progression or death during weeks 0 to 8 was higher in the cilta-cel group and all occurred before cilta-cel infusion; this may have been due to lower bridging doses of DPd/PVd, and the benefit did not become apparent until 3 months. Overall survival data were immature.
- Evident: the trial was open-label, the sponsor was involved in data collection, analysis, and interpretation, and median follow-up was 15.9 months, limiting assessment of overall survival; crossover from standard care to cilta-cel was not permitted.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
17 Valid · 2 Not valid · 4 Not checked · 86 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“In the phase 1b-2 CARTITUDE-1 trial involving patients who had received at least three lines of therapy, the median progressionfree survival was 34.9 months. 10-12”
What the sources say
- Not checked — no full text of the sourcecites [10] 10. Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet 2021; 398: 314-24. source
- Disputedcites [11] 11. Martin T, Usmani SZ, Berdeja JG, et al. Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol 2023; 41: 1265-74. sourceExperimental — accuracy not yet measured
The Results > Efficacy section states that median progression-free survival was not reached at a median follow-up of 27.7 months, contrary to the claimed 34.9 months. The Methods > Study Design and Treatment section confirms that CARTITUDE-1 was a phase Ib/II trial, but its eligibility criteria also allowed some patients with fewer than three prior lines of therapy. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
- Not checked — no full text of the sourcecites [12] 12. Lin Y, Martin TG, Usmani SZ, et al. CARTITUDE-1 final results: phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/ refractory multiple myeloma. J Clin Oncol 2023; 41: Suppl: 8009. abstract. source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“High treatment attrition - only 13 to 35% of patients receive four or more lines of therapy - also highlights the need to use effective therapies early. 9”
What the sources say
- Supportedcites [9] 9. Fonseca R, Usmani SZ, Mehra M, et al. Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma. BMC Cancer 2020; 20: 1087. source
Table 4 (Results, Attrition by LOT) shows that 2,971 of 22,062 non-transplant patients (13.5%) and 954 of 2,763 transplant patients (34.5%) received a fourth line of therapy. The Conclusion links high attrition to the need for effective treatment early. These percentages concern patients in the study who received at least one line of therapy, not all patients diagnosed with multiple myeloma. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The frequency of lenalidomide resistance early in the treatment journey is increasing, 1,8”
What the sources say
- Supportedcites [1] 1. van de Donk NWCJ. Sequencing multiple myeloma therapies with and after antibody therapies. Hematology Am Soc Hematol Educ Program 2020; 2020: 248-58. source
In the Introduction sections “Changes in frontline treatment” and “Refractory to lenalidomide,” the paper says that increasing frontline use of lenalidomide is leading to an increasing fraction of patients with lenalidomide-refractory disease at first relapse. This supports the claim about resistance occurring more frequently early in the treatment journey. (LLM, conf=0.94)
- Supportedcites [8] 8. de Arriba de la Fuente F, Montes Gaisán C, de la Rubia Comos J. How to manage patients with lenalidomide-refractory multiple myeloma. Cancers (Basel) 2022; 15: 155. source
The Introduction states that, with extensive use of frontline lenalidomide-based therapies, lenalidomide refractoriness early in the disease course is increasingly common. This directly supports the citing sentence’s paraphrase. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The incidence of movement and neurocognitive adverse events was also lower in CARTITUDE-4 (0.6%) than in CARTITUDE-1 (6.0%)”
What the sources say
- Not checked — no full text of the sourcecites [10] 10. Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet 2021; 398: 314-24. source
- Partly supportedcites [11] 11. Martin T, Usmani SZ, Berdeja JG, et al. Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol 2023; 41: 1265-74. sourceExperimental — accuracy not yet measured
The Results section identifies parkinsonism as previously termed movement and neurocognitive adverse events, and the Discussion reports a 6% incidence in CARTITUDE-1. The paper does not give a CARTITUDE-4 incidence of 0.6%; it instead reports less than 0.5% across other cilta-cel studies without identifying CARTITUDE-4. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“which suggests that cilta-cel may have a better side-effect profile when used earlier in treatment. 10,11”
What the sources say
- Not checked — no full text of the sourcecites [10] 10. Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet 2021; 398: 314-24. source
- Partly supportedcites [11] 11. Martin T, Usmani SZ, Berdeja JG, et al. Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol 2023; 41: 1265-74. sourceExperimental — accuracy not yet measured
The Discussion (page not available) says earlier use of cilta-cel may improve long-term outcomes and notes that prior treatments in this heavily pretreated group are associated with an increased risk of secondary primary malignancies. It does not say that cilta-cel itself would have fewer side effects if used earlier, so the specific safety comparison remains unsupported. (LLM, conf=0.78)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
43 more claims
Create a free account to see all 109 claims and every source verdict.
- Probably not a substantial claim. 35
- It may state two separate claims as one. 30
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The proportion of patients over age 75 years or with an Eastern Cooperative Oncology Group performance status score of 2 were also small but consistent with results reported in studies of similar populations;5,26,28,33 a progression-free survival benefit was still observed with Tec-Dara in these subgroups.”
From Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma (2026) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Patients in the cilta-cel arm of CARTITUDE-4 who had increased tumor burden after bridging therapy or lymphodepletion were assessed as having PD and could receive cilta-cel as subsequent therapy at the investigator ' s discretion 14 ; in KarMMa-3, these patients were permitted to remain on study.”
From Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses. (2024) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Notably in KarMMa-3, 54% (207/386) of patients were enrolled in the United States compared with 15% (64/419) in CARTITUDE-4. 14”
From Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses. (2024) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Ciltacabtagene autoleucel, a BCMA autologous CAR-T therapy, has significantly improved progression-free and overall survival versus DPd/PVd, with an improving adverse event profile from late to earlier lines of treatment.5,25”
From Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma (2026) · cites this paper as [5]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Both ide-cel and cilta-cel have subsequently shown superiority over standard relapsed myeloma regimens in randomized trials conducted earlier in the disease course (Table 9).159,160”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [160]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“During treatment, infections occurred in 129 patients (62.0%) in the cilta-cel group and in 148 (71.2%) in the standard-care group; of these infections, 26.9% and 24.5%, respectively, were of grade 3 or 4.”
Reported 26.9 · recomputed 43.410853
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“| Immune effector cell-associated neuro- toxicity syndrome and associated symptoms | 8/176 (4.5) | 1/176 (0.1)”
Reported 0.1 · recomputed 0.568182
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“MRD negativity at any time during the trial occurred in 60.6% of the patients in the cilta-cel group and in 15.6% of those in the standard-care group, for a risk ratio of 2.2”
Reported 2.2 · recomputed 3.884615
Citations
Cites
Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J. H., Mead, E., Pavletic, S., et al. (2019) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2018.12.758 · Cited by 3,675
Berdeja, J. G., Madduri, D., Usmani, S. Z., Jakubowiak, A., Agha, M., Cohen, A. D., Stewart, A. K., Hari, P., Htut, M., Lesokhin, A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00933-8 · Cited by 1,756
Self-citationDaratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Palumbo, A., Chanan-Khan, A., Weisel, K., Nooka, A. K., Masszi, T., Beksac, M., Spicka, I., Hungria, V., Munder, M., Mateos, M. V., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606038 · Cited by 1,522
Self-citationRajkumar, S. V., Harousseau, J.-L., Durie, B., Anderson, K. C., Dimopoulos, M., Kyle, R., Blade, J., Richardson, P., Orlowski, R., Siegel, D., et al. (2011) · Blood · doi:10.1182/blood-2010-10-299487 · Cited by 1,036
Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
Dimopoulos, M. A., Moreau, P., Terpos, E., Mateos, M. V., Zweegman, S., Cook, G., Delforge, M., Hájek, R., Schjesvold, F., Cavo, M., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.11.014 · Cited by 900
Self-citationIde-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma
Rodriguez-Otero, P., Ailawadhi, S., Arnulf, B., Patel, K., Cavo, M., Nooka, A. K., Manier, S., Callander, N., Costa, L. J., Vij, R., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2213614 · Cited by 781
Self-citationMartin, T., Usmani, S. Z., Berdeja, J. G., Agha, M., Cohen, A. D., Hari, P., Avigan, D., Deol, A., Htut, M., Lesokhin, A., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.00842 · Cited by 663
Self-citationDimopoulos, M., Quach, H., Mateos, M.-V., Landgren, O., Leleu, X., Siegel, D., Weisel, K., Yang, H., Klippel, Z., Zahlten-Kumeli, A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30734-0 · Cited by 430
Self-citationMoreau, P., Dimopoulos, M.-A., Mikhael, J., Yong, K., Capra, M., Facon, T., Hajek, R., Špička, I., Baker, R., Kim, K., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00592-4 · Cited by 392
Self-citationRichardson, P. G., Oriol, A., Beksac, M., Liberati, A. M., Galli, M., Schjesvold, F., Lindsay, J., Weisel, K., White, D., Facon, T., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30152-4 · Cited by 386
Self-citation
Cited by
Items 201–300 of 814
Hansen, D. K., Lu, X., Puglianini, O. A. C., Sorensen, S. V., Usmani, S. Z., Zhang, E., Huo, S., Zhang, Y., Qureshi, Z. P., & Jagannath, S. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1408892 · Cited by 12
Nivolumab to restore T-cell fitness in CAR-T refractory multiple myeloma
Waldschmidt, J. M., Sotudeh, N., Arora, S., Vijaykumar, T., Anand, P., Stuart, H., Frede, J., Campbell, T., Kaiser, S. M., Zheng, X., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024015285 · Cited by 10
Self-citationMajhail, N. S., Cox, T., Larson, S., Battiwalla, M., Ramakrishnan, A., Shaughnessy, P. J., Tees, M. T., Zahradka, N., Wilkes, M., & Pantin, J. M. (2025) · JCO Oncology Practice · doi:10.1200/op-25-00062 · Cited by 14
Fair Allocation of Scarce CAR T-Cell Therapies for Relapsed/Refractory Multiple Myeloma
Derman, B. A., & Parker, W. F. (2023) · JAMA · doi:10.1001/jama.2023.11846 · Cited by 11
Fang, J., & Zhou, F. (2023) · Annals of Hematology · doi:10.1007/s00277-023-05444-7 · Cited by 13
Pereira, R., & Bergantim, R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25094996 · Cited by 12
Toxicity of CAR T-Cell Therapy for Multiple Myeloma
Afrough, A., Abraham, P. R., Turer, L., Kaur, G., Sannareddy, A., Hansen, D. K., & Anderson, L. D. (2024) · Acta Haematologica · doi:10.1159/000539134 · Cited by 16
“%) with CAR-T-related peripheral neuropathy [21, 37, 41].”
InfluentialFirst report of teclistamab in a patient with relapsed AL amyloidosis and multiple myeloma
Leung, N., Chapman, J. A., & Bhatia, S. (2023) · eJHaem · doi:10.1002/jha2.772 · Cited by 10
“S.FoodandDrugAdministration(FDA)forpatientswithrelapsed or refractory MM [10–13].”
Treatment of Multiple Myeloma: ASCO–Ontario Health (Cancer Care Ontario) Living Guideline
Hicks, L. K., Messersmith, H. J., Hadidi, S. S. A. A., Banerjee, R. K., Derman, B. A., Kumar, S. K., Wildes, T. M., Bal, S., Bhella, S., Chmielewski, C., et al. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-25-02587 · Cited by 17
Cilta-cel, a BCMA-targeting CAR-T therapy for patients with multiple myeloma
Jagannath, S., Jackson, C. C., Schecter, J. M., Lendvai, N. K., Sun, H., Akram, M., Patel, N., & Martin, T. G. (2024) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2024.2352591 · Cited by 15
“The primary endpoint in CARTITUDE-4 was PFS. Secondary efficacy outcomes were rates of patients achieving at least a CR, ORR, MRD negativity (10 −5 detection level), OS, time to patient-reported symptom worsening, and safety (adverse events) [12].”
BackgroundMethodResultInfluentialSelf-citationHamadeh, I. S., Friend, R. N., Mailankody, S., & Atrash, S. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1455464 · Cited by 10
Grégoire, C., de Oliveira, B. C., Caimi, P. F., Caers, J., & Melenhorst, J. J. (2024) · British Journal of Haematology · doi:10.1111/bjh.19751 · Cited by 14
“35,36 Similar to the trend in B-cell malignancies, the benefits of CAR T cells when used as an earlier line of therapy in multiple myeloma is currently being explored, and Cilta-cel has been recently approved by the Food and Drug Administration (FDA) in patients with R/R multiple myeloma who have…”
CAR T-cell therapy to treat multiple myeloma: current state and future directions
Reddy, S. T., Hosoya, H., & Mikkilineni, L. (2024) · Cancer and Metastasis Reviews · doi:10.1007/s10555-024-10219-1 · Cited by 13
“To date, one patient experienced a grade 1 MNT event, 16 patients had cranial nerve palsies, and 5 patients had CAR-T related peripheral neuropathies [10].”
InfluentialZhou, X., Kortuem, K. M., Rasche, L., & Einsele, H. (2024) · La Presse Médicale · doi:10.1016/j.lpm.2024.104265 · Cited by 14
Self-citationIberdomide, ixazomib and dexamethasone in elderly patients with multiple myeloma at first relapse
Touzeau, C., Leleu, X. P., Tiab, M., Macro, M., Perrot, A., Gay, J., Chateleix, C., Moreau, S., Karlin, L., Jacquet, C., et al. (2025) · British Journal of Haematology · doi:10.1111/bjh.19978 · Cited by 13
“21,22 However, a very scarce proportion of patients were aged over 70years and the safety of chimeric antigen receptor T-cell therapy targeting B-cell maturation antigen (BCMA) in older patients still needs to be demonstrated.”
Self-citationNovel Treatment Options for Multiple Myeloma
Portuguese, A. J., Banerjee, R. K., Chen, G. Z., Reddi, S., & Cowan, A. J. (2025) · JCO Oncology Practice · doi:10.1200/op-24-00752 · Cited by 17
Forcing Ahead: Second-Line Treatment Options for Lenalidomide-Refractory Multiple Myeloma
Mancuso, K., Barbato, S., Raimondo, F. D., Gay, F., Musto, P., Offidani, M., Petrucci, M. T., Zamagni, E., Zambello, R., & Cavo, M. (2025) · Cancers · doi:10.3390/cancers17071168 · Cited by 10
“…mafodotin (B), initially tested as monotherapy in the DREAMM-2 trial [84] and subsequently compared with Pd in the DREAMM-3 study [85], was further evaluated in the large phase 3 randomized trials DREAMM-7 and DREAMM-8 in the setting of len-exposed and len-refractory RRMM patients after at least…”
Self-citationEmapalumab for severe cytokine release syndrome in solid tumor CAR-T: a case report
Ruemmele, T., Macedo, R., Stein, M. N., Chan, H. T., Mapara, M. Y., Jacquemont, C. F., & Reshef, R. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1543622 · Cited by 9
Kannan, A., Jeffrey, K., Misbah, S., & Ramasamy, K. (2025) · Blood Reviews · doi:10.1016/j.blre.2025.101287 · Cited by 13
An, N., Li, J., Luo, P., Wang, D., Zhang, P., Shu, C., Cai, S., Yu, Q., Wen, X., Wang, X., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06543-x · Cited by 12
“Recent clinical trials (KarMMa-3, CARTITUDE-4, CARTITUDE-2) have demonstrated favorable efficacy of BCMA CAR-T therapy in patients with early relapse or lenalidomide-refractory disease [6, 39, 40].”
Fu, W., Chen, J., & Hu, X. (2025) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2025.101634 · Cited by 15
Anitha, K., Chenchula, S., Vardhan, K. V., Padmavathi, R., Varshini, T. S., Amerneni, L. S., Amerneni, K. C., & Chavan, M. R. (2025) · Medical Oncology · doi:10.1007/s12032-025-02923-x · Cited by 15
“Key clinical outcomes of CAR-T-cell therapies targeting BCMA and CD19 are summarized in Table 2 [112–115, 118, 119, 125–127, 141, 150–155], with recent updates confirming efficacy in diverse populations [116, 117, 120–124, 128–131, 134–140, 143–149, 156–162].”
Naik, S., Aplenc, R., Baumeister, S. H. C., Becilli, M., Bhagwat, A. S., Bonifant, C. L., Budde, L. E., Chien, C. D., Curran, K. J., Daniyan, A. F., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025017011 · Cited by 11
“1-12 In contrast, clinical experience with CAR T cells for patients with acute myeloid leukemia (AML) has been beset by low response rates.”
Recent advances in cellular immunotherapy for lymphoid malignancies
Chung, H., & Cho, H. (2023) · Blood Research · doi:10.5045/br.2023.2023177 · Cited by 10
“The KarMMa-3 and CARTITUDE-4 trials demonstrated superior progression-free survival with CAR-T cells compared with standard-of-care combinations in earlier lines of MM treatment [36, 37].”
BackgroundIntegrating Immune Therapies for the Treatment of Multiple Myeloma
Mikkilineni, L., & Sidana, S. (2023) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2023.7100 · Cited by 10
Self-citationLupia, T., Cani, L., Bringhen, S., Rosa, F. G. D., Bruno, B., Mikulska, M., Corcione, S., & Mina, R. (2024) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2024.05.002 · Cited by 9
Martino, M. V., Gamberi, B., Antonioli, E., Aquino, S., Pepa, R. D., Malerba, L., Mangiacavalli, S., Pezzatti, S., Bringhen, S., & Zamagni, E. (2024) · Expert Review of Hematology · doi:10.1080/17474086.2024.2357274 · Cited by 11
“…PFS was 75.9% in the cilta-cel group and 48.6% in the standard-care group, independently of the regimen used (i.e. DPd or PVd), with 73.1% and 21.8% of patients achieving a complete response or better (ORR being 84.6% and 67.3), and MRD-negativity found in 60.6% vs 15.6%, respectively [36].”
BackgroundMethodInfluentialLiu, W., Lin, S., Zhu, X., Yin, L., Liu, Q., Lei, S., & Feng, B. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1433075 · Cited by 9
Lebel, E., Vainstein, V., Milani, P., Palladini, G. O., Shragai, T., Lavi, N., Magen, H., Assayag, M., Avivi, I. M., & Gatt, M. E. (2024) · Acta Haematologica · doi:10.1159/000541594 · Cited by 10
Self-citationAvigan, Z. M., Bodnar, S., Pan, D., Catlett, J. L., Richter, J. R., Sanchez, L. J., Rodriguez, C., Rossi, A., Richard, S., Jagannath, S., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024014255 · Cited by 10
Xu, Y., Zhang, X., Xin, D., Zhang, J., Wang, L., Fan, Y., Chen, B., Lei, W., Qiu, X., Jiang, H., et al. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-24-0051 · Cited by 14
Yan, W., Xiong, Y., Lv, R., Du, C., Yu, T., Zhang, S., Sui, W., Deng, S., Xiao, J., Xu, Y., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010080 · Cited by 10
Unmet needs and lived experience of patients receiving CAR T-cell therapy
O'Shea, P. G., Johnson, P. C., El-Jawahri, A. R., & LeBlanc, T. W. (2025) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2025.2455488 · Cited by 9
“though there is significant and promising improvement in progression-free and overall survival in cAR-t therapies for various hematological malignancies, the majority of patients will unfortunately ultimately have disease progression, often with significant toxicities in the interim [1–7].”
CAR‐T cells in the treatment of multiple myeloma: an encouraging cell therapy
Yu, T., Jiao, J., & Wu, M. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1499590 · Cited by 15
Bhatnagar, V., Dueck, A. C., Efficace, F., Kluetz, P. G., Minasian, L. M., Velikova, G., Drew, C., & Thanarajasingam, G. (2025) · The Lancet Haematology · doi:10.1016/s2352-3026(25)00036-5 · Cited by 9
Management recommendations for kidney transplantation in patients with plasma cell dyscrasia
Murakami, N., Blosser, C. D., Webber, A. B., Gupta, G., Singh, N., Boppana, S., Master, S. R., Parasuraman, R. K., Campagnaro, E. L., Java, A., et al. (2025) · Kidney International · doi:10.1016/j.kint.2025.07.011 · Cited by 11
der Vreken, A. V., Meeus, F., Tu, C., van den Broecke, L., Raimondi, V., Vescovini, R., Hanssens, H., Watté, F., Autaers, D., Aragon, M. M., et al. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01756-5 · Cited by 10
Tseng, H., Dholaria, B., Cranert, S. A., Richter, M., Marquez, K., Cho, B. S., Bacong, A., McArthur, K., Eskew, J. D., McCaigue, J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-65267-0 · Cited by 10
“cytokine release syndrome (CRS) 1 – 3 .”
Hosoya, H., Torres, A. N. B., Fernandez‐Pol, S., Gubatan, J. M. B., Najidh, S., Durán, G. E., Dong, F., Ehlinger, Z. J., Lohman, C., Wright, C., et al. (2025) · Blood · doi:10.1182/blood.2025031423 · Cited by 10
Self-citationRodríguez‐Otero, P., Sidana, S., Kouwenhoven, M. C. M., Schecter, J. M., Lendvai, N. K., Braganca, K. C. D., Slaughter, A., Lonardi, C., Vlummens, P., Varsos, H., et al. (2025) · Blood Cancer Journal · doi:10.1038/s41408-025-01410-w · Cited by 12
Self-citationRuxolitinib for ciltacabtagene autoleucel–associated refractory diarrhea
Blumenberg, V., Birocchi, F., Shih, A., Escobar, G., Mucci, A., Armstrong, A., Cirstea, D. D., Harris, D. L., Bozym, D. J., Puliafito, B. R., et al. (2026) · Blood · doi:10.1182/blood.2025032347 · Cited by 8
Cani, L., Parikh, R., Joseph, N. S., Gupta, V. A., Hofmeister, C. C., Kaufman, J. L., Nooka, A. K., Lonial, S., & Mina, R. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2026.03.003 · Cited by 8
Update on the current and future use of CAR‐T to treat multiple myeloma
Gahvari, Z. J., Brunner, M., Schmidt, T. M., & Callander, N. S. (2023) · European Journal Of Haematology · doi:10.1111/ejh.14145 · Cited by 12
Wiedemann, G., Bacher, U., Joncourt, R., Solly, F., Widmer, C. C., Zeerleder, S. S., Novak, U., Pabst, T., & Porret, N. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168556 · Cited by 8
Su, M., Dey, A., Maddah, E., Mugundu, G. M., & Singh, A. P. (2024) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.13259 · Cited by 9
Cellular Therapies for Multiple Myeloma: Engineering Hope
Vera-Cruz, S., Culubret, M., Konetzki, V., Alb, M., Friedel, S. R., Hudecek, M., Einsele, H., Danhof, S., & Scheller, L. (2024) · Cancers · doi:10.3390/cancers16223867 · Cited by 9
Self-citationSupportive care in myeloma—when treating the clone alone is not enough
Zweegman, S., & van de Donk, N. W. C. J. (2024) · Hematology · doi:10.1182/hematology.2024000579 · Cited by 8
Self-citationCurrent Treatment Strategies for Multiple Myeloma at First Relapse
Mavrothalassitis, E., Triantafyllakis, K., Malandrakis, P., Gavriatopoulou, M., Kleber, M., & Ntanasis‐Stathopoulos, I. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14051655 · Cited by 7
“Death from any cause was reported in 39 patients and 46 patients, respectively (HR, 0.78; 95% CI, 0.5 to 1.2) [40].”
InfluentialEmerging Strategies of Cell and Gene Therapy Targeting Tumor Immune Microenvironment
Wang, R., Duan, X., Li, J., Zhang, C., & Shen, L. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-4308 · Cited by 10
“This study led to the FDA’s updated approval in April 2024, allowing Carvykti to be used for patients who had undergone one to three prior therapies (121).”
CD95/Fas stoichiometry in future precision medicine
Sica, M. P., Roussel, M., & Legembre, P. (2025) · Cell Death and Differentiation · doi:10.1038/s41418-025-01493-9 · Cited by 13
Lund, T., Khandanpour, C., Anguille, S., Kisro, J., Krauth, M. T., Lund, J., Nijhof, I. S., Ocio, E. M., Zamagni, E., Javelot, M., et al. (2025) · European Journal Of Haematology · doi:10.1111/ejh.14444 · Cited by 9
Self-citationZhang, X., Wang, L., Yang, J., Hu, X. N., Wang, H., Zhang, L., Zhou, X., Liu, Y., Wang, Q., & Lu, P. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025016322 · Cited by 10
Ntanasis‐Stathopoulos, I., Filippatos, C., Malandrakis, P., Koutoulidis, V., Trapali, M., Kastritis, E., Terpos, E., Dimopoulos, M. A., & Gavriatopoulou, M. (2025) · Leukemia · doi:10.1038/s41375-025-02677-5 · Cited by 8
Ailawadhi, S., Anderson, L. D., Dhakal, B., Shune, L. O., Sborov, D. W., & Hansen, D. K. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.08.005 · Cited by 14
Self-citationCAR T cell–mediated bone marrow inflammation causes hematotoxicity and favors clonal hematopoiesis
Khelil, M. B., Arbab, A., Srikanthan, J., Marcos-Kovandzic, L., Vergé, V., Pagès, A., Rengassamy, J., Amine-Hneineh, R., Aglave, M., Jelin, R., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adu9790 · Cited by 17
Filippatos, C., Kanteli, I., Pasipoularidou, D. G., Gavriatopoulou, M., Tentolouris, A., Malandrakis, P., Sergentanis, T. Ν., Terpos, E., & Ntanasis‐Stathopoulos, I. (2026) · American Journal of Hematology · doi:10.1002/ajh.70201 · Cited by 11
Baena, J. C., Cabrera-Salcedo, S. C., Suárez, Y. C., Biancha‐Vasco, J. M., Ríos-Serna, L. J., García-Mantilla, M. D., Estrada, M., Hincapie, J. S. V., Toro-Pedroza, A., García-Robledo, J. E., et al. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04089-8 · Cited by 10
“…remission in relapsed acute lymphoblastic leukemia and 82% objective response in lymphoma [138, 139], and BCMA CAR-T achieving 73–84.6% overall response in multiple myeloma [140, 141], they are frequently limited by CRS, ICANS, GvHD, and poor penetration into the immunosuppressive TME [142, 143].”
InfluentialClinical progress of engineered cellular immunotherapies for autoimmunity
Solimani, F., Amagai, M., Bollard, C. M., & Payne, A. S. (2026) · Nature Biotechnology · doi:10.1038/s41587-026-03001-x · Cited by 9
Measurable residual disease in peripheral blood in myeloma: dream or reality
Kubicki, T., Derman, B. A., Dytfeld, D., & Jakubowiak, A. J. (2023) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000987 · Cited by 7
Self-citationCanichella, M., Molica, M., Mazzone, C., & de Fabritiis, P. (2023) · Cancers · doi:10.3390/cancers16010042 · Cited by 7
“…large B-cell lymphoma In the hematological fi eld, CAR-T-cell therapy had produced signi fi cant results in the treatment of R/R di ff use large B-cell lymphoma (DLBCL), mantle-cells lymphoma (MCL), follicular lymphoma, B-cell acute lymphoblastic leukemia (B-ALL), and R/R multiple myeloma (MM) [3–13].”
BackgroundKastritis, E., Ntanasis‐Stathopoulos, I., Theodorakakou, F., Migkou, M., Ρούσσου, Μ., Malandrakis, P., Kanellias, N., Eleutherakis‐Papaiakovou, E., Fotiou, D., Spiliopoulou, V., et al. (2024) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2024.03.003 · Cited by 9
BCMA-directed therapy for early relapsed and/or refractory multiple myeloma
van de Donk, N. W. C. J., & Zweegman, S. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00927-6 · Cited by 8
“…and ciltacabtagene autoleucel were recently approved by the FDA and EMA for the early line treatment of RRMM, on the basis of superior response rates and PFS compared to standard triplet-regimens, including DVd and PVd, respectively, in the phase III KarMMa-3 and CARTITUDE-4 trials 7,8 (Fig.”
Self-citationMidha, S., Hartley-Brown, M. A., Mo, C. C., Hossain, S., Nadeem, O., O’Donnell, E., Bianchi, G., Sperling, A. S., Laubach, J. P., & Richardson, P. G. G. (2023) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2023.2274420 · Cited by 8
“The common toxicities reported in key studies of these agents, including the KarMMa series of studies of ide-cel [103–105] and the CARTITUDE studies of cilta-cel [106–110], are summarized in Table 2, along with the first data reported for the GPRC5D-targeted CAR T cell therapy MCARH109 [111].”
BackgroundStraßl, I., & Podar, K. (2024) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2024.2319672 · Cited by 8
“CRS is expected in the majority of patients after Cilta-cel administration [44,56,66,69,84,85].”
BackgroundInfluentialBCMA-Directed MRD Detection as a Predictor of Relapse after BCMA CAR T in Multiple Myeloma
Rashid, A., Wesson, W., Abdallah, A.-O. A., Snyder, J. A., Venkatesh, P., Mushtaq, M. U., Shune, L. O., Witek, M. A., McGuirk, J. P., Soper, S. A., et al. (2024) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2024.10.003 · Cited by 8
Mancuso, K., Talarico, M., Manzato, E., Barbato, S., Tacchetti, P., Zamagni, E., & Cavo, M. (2025) · Cancers · doi:10.3390/cancers17091514 · Cited by 12
Self-citationGlobal Access to Multiple Myeloma Therapies
Atallah, R., Shatnawi, Y., Ayoobkhan, F. S., Saif, M. S. I., Naeem, M., Logan, E., Mushtaq, M. U., Rana, S., Mammadzadeh, A., Hashmi, S. K., et al. (2025) · JCO Global Oncology · doi:10.1200/go-24-00441 · Cited by 10
“50-52 50-52 The high cost of MM drugs is a fi nancial burden, even in countries with universal health coverage, and can strain their resources.”
Self-citationWu, B. X., Kreatsoulas, D. C., Çam, H., Bolyard, C. M., Chang, Y., Mandula, J. K., Welsh, P. W., Wang, Z., Li, A., Weltge, P., et al. (2025) · Neuro-Oncology · doi:10.1093/neuonc/noaf195 · Cited by 8
“To date, most clinical success with CAR-T therapy has been reported in hematologic cancers 22,23 ; however, ongoing research aims to identify new antigens to target a range of solid malignancies, including GBM. 24 CAR-T-targeted antigens in GBM include interleukin-13 receptor alpha2 (IL13R α 2), 25…”
Hansen, D. K., Dima, D., Mian, H. S., DeVos, J. D., Brazauskas, R., Oloyede, T., Afrough, A., Ahmed, N., Anderson, L. D., Banerjee, R., et al. (2025) · Blood Cancer Journal · doi:10.1016/s2152-2650(25)03469-x · Cited by 7
Self-citationMoreno‐Castaño, A. B., Iraola, G., Martínez‐Cibrián, N., Albiol, N., Prats, D.-N. M., Martínez-Sánchez, J., Castro, P., & Díaz‐Ricart, M. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1699894 · Cited by 8
Cardiotoxicity of T cell immunotherapies
Raddatz, M. A., Stein-Merlob, A. F., Mahmood, S. S., Ganatra, S., Addison, D., Lin, T. L., Larson, S. M., & Yang, E. H. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-026-01265-z · Cited by 9
Xu, X., Gu, H., Cha, Z., Zhang, B., Yuan, S., Ding, X., Gao, L., Gao, S., Wu, X., Gu, L., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.03.012 · Cited by 10
Aleksandrova, Y. R., Munkuev, A. A., Mozhaitsev, E. S., Суслов, Е. В., Volcho, K. P., Salakhutdinov, N. F., & Неганова, М. Е. (2023) · Cancers · doi:10.3390/cancers15204985 · Cited by 6
“…could reverse therapeutic resistance and increase the effectiveness of treatment without increasing side effects on a healthy microenvironment [8–12]. practice, three representatives of this class are already actively used as powerful antitumor agents due to their excellent inhibitory…”
BackgroundSingh, K., Rocco, J. M., & Nussenblatt, V. R. (2024) · Seminars in Hematology · doi:10.1053/j.seminhematol.2024.08.002 · Cited by 6
Nunes, F., Gusmão, B. M. D., Wiginesk, F. B., Manenti, E. R. F., Soares, J., Freitas, M. G., Seabra-Garcez, J. D., Varela, A., Dutra, J. P. P., Bacchiega, B. C., et al. (2024) · Hematology Transfusion and Cell Therapy · doi:10.1016/j.htct.2024.06.008 · Cited by 6
Guo, J., Wu, Q., Li, H., Liang, C., Dai, J., Zhang, S., Dai, C., Zhang, J., Wen, Y., & Yang, W. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1435934 · Cited by 7
Esquinas, E., Moreno-Sanz, A., Sandá, V., Stodulski, D., Borregón, J., Peña-Blanque, V., Fernández-Calles, J., Fernández‐Fuentes, N., Serrano‐López, J., Juan, M., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009485 · Cited by 8
Current State of Evidence on Definitions and Management of High-Risk Multiple Myeloma
Lal, B. M., van Rhee, F., & Hadidi, S. A. (2025) · Current Oncology Reports · doi:10.1007/s11912-025-01639-5 · Cited by 8
“The PFS benefit was maintained in patients with HRCAs (HR: 0.25, 95% CI: 0.16–0.38) [124].”
InfluentialBasic Concepts and Indications of CAR T Cells
van den Berg, J., Laubli, H. P., Khanna, N., Jeker, L. T., & Holbro, A. (2025) · Hämostaseologie · doi:10.1055/a-2491-3652 · Cited by 11
Goel, U., Zanwar, S., Cowan, A. J., Banerjee, R. K., Khouri, J., & Dima, D. (2025) · Cancer Management and Research · doi:10.2147/cmar.s510408 · Cited by 8
“12 After the successful manufacturing of CAR T-cells, patients undergo lymphodepletion therapy with most commonly fludarabine and cyclophosphamide (standard of care) or other regimens based on institutional protocols.”
InfluentialKikuchi, T., Watanabe, M., Tsukada, N., Matsumoto, C., Nomura‐Yogo, M., Kunisada, K., Sawada, H., Sato, K., Takei, T., Ogura, M., et al. (2025) · Transplant Infectious Disease · doi:10.1111/tid.70040 · Cited by 6
“In recent years, the advent of chimeric antigen receptor T-cell (CAR-T) therapy has improved the treatment outcomes for patients with TCE MM [5–8].”
Self-citationLiao, Y., Hsu, S., & Chiou, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25042416 · Cited by 7
Targeting GPRC5D in multiple myeloma
Elemian, S., & Hadidi, S. A. (2024) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2024.2343114 · Cited by 7
Rare Adverse Events of CAR T-Cell Therapy
Müller, A. M. S. (2024) · healthbook TIMES Oncology Hematology · doi:10.36000/hbt.oh.2024.19.138 · Cited by 8
China's potential role in humanitarian assistance
Binder, A., & Conrad, B. (2009) · Cited by 9
Aiming for the cure in myeloma: Putting our best foot forward
Bar, N., Firestone, R., & Usmani, S. Z. (2023) · Blood Reviews · doi:10.1016/j.blre.2023.101116 · Cited by 6
SOHO State of the Art Updates and Next Questions: Will CAR-T Replace ASCT in NDMM
Jurgens, E. M., & Usmani, S. Z. (2024) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2024.01.001 · Cited by 6
License for a CAR T: Examining patient eligibility
Akkad, N., & Chihara, D. (2024) · Seminars in Hematology · doi:10.1053/j.seminhematol.2024.07.001 · Cited by 6
Costa, B. A., Dima, D., Mark, T. M., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14041316 · Cited by 5
“Based on results of the KarMMa and CARTITUDE trials [1,2], two commercial products are currently approved for routine use in patients with both early and later lines of treatment: idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel).”
Alsina, M., Dhakal, B., Pantin, J. M., Huff, C. A., & Janakiram, M. (2025) · Future Oncology · doi:10.1080/14796694.2025.2476382 · Cited by 6
“This is based on outcomes from the CARTITUDE-1 and CARTITUDE-4 trials, where the median time to onset of CRS (7–8 days) and ICANS (8–9.5 days) was after 1 week (Table 2) [15,18].”
InfluentialSelf-citationMalignancies after Chimeric Antigen Receptor T Cell Therapy
Mohty, R., Halwani, A., Badar, T., Alkhateeb, H. B., Shah, M. V., Qin, H., & Kharfan‐Dabaja, M. A. (2025) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2025.06.001 · Cited by 8
Martino, E. A., Caridà, G., Lofaro, D., Bruzzese, A., Labanca, C., Mendicino, F., Lucia, E., Olivito, V., Puccio, N., Neri, A., et al. (2025) · ESMO Open · doi:10.1016/j.esmoop.2025.105514 · Cited by 7
Paruzzo, L., Eshaghi, K., Ghilardi, G., Doucette, A. G., Ho, M., Carturan, A., Vogl, D. T., Waxman, A. J., Kapur, S., Fardella, E., et al. (2025) · Blood Immunology & Cellular Therapy · doi:10.1016/j.bict.2025.100007 · Cited by 6
Chen, W., Cai, Z., Chim, C. S., Chng, W. J., Du, J., Fu, C., Gao, W., Hanamura, I., Hou, J. M., Huang, J., et al. (2025) · Clinical Hematology International · doi:10.46989/001c.141401 · Cited by 6
Self-citationRedefining multiple myeloma treatment: Advances, challenges, and future directions in immunotherapy
Fu, C., Zhai, Y., Yan, L., Jin, S. L., Shang, J., Shi, X., & Wu, D. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003655 · Cited by 9
“Unlike idecabtagene vicleucel (ide-cel) [75] and ciltacabtagene autoleucel (cilta-cel), [76] along with dual antibodies and other BCMA-targeted approaches, eque-cabtagene autoleucel (eque-cel, CT103A) [5] represents a significant advancement by circumventing the negative impact of sBCMA, ensuring…”
A clonally expanded nodal T-cell population diagnosed as T-cell lymphoma after CAR-T therapy
Maurer, K., Weir, J. A., Nagler, A., Haradhvala, N. J., Bharadwaj, H., Shapiro, J., Alakwe, S. D., Kumar, V., Waller, B. F., McDonough, M. M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-62709-7 · Cited by 10
Zayad, A., Magee, G., Mansour, R. A., Chang, M., Ahmed, N., Mushtaq, M. U., Paul, B. A., Green, K. M., Davis, J. A., Skikne, B., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.08.017 · Cited by 6
The role of stem cell transplantation in the modern management of multiple myeloma
Villar, S., Zapata, E., & Rifón, J. (2025) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000896 · Cited by 4
Pleitez, H. J. G., Saowapa, S., Maldonado, A., Kanitthamniyom, C., Bernal, D. A. O., & Tijani, L. (2025) · European Journal Of Haematology · doi:10.1111/ejh.70025 · Cited by 7
Abuhelwa, Z., Amisha, F., Fan, W., Avila, G. D., Hansen, D. K., Grajales-Cruz, A. F., Blue, B. J., Puglianini, O. A. C., Liu, H. D., Freeman, C. L., et al. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1663814 · Cited by 9
Metadata
- Authors
- San-Miguel, J., Dhakal, B., Yong, K., Spencer, A., Anguille, S., Mateos, M.-V., Fernández de Larrea, C., Martínez-López, J., Moreau, P., Touzeau, C., Leleu, X., Avivi, I., Cavo, M., Ishida, T., Kim, S. J., Roeloffzen, W., van de Donk, N. W. C. J., Dytfeld, D., Sidana, S., Costa, L. J., Oriol, A., Popat, R., Khan, A. M., Cohen, Y. C., Ho, P. J., Griffin, J., Lendvai, N., Lonardi, C., Slaughter, A., Schecter, J. M., Jackson, C. C., Connors, K., Li, K., Zudaire, E., Chen, D., Gilbert, J., Yeh, T.-M., Nagle, S., Florendo, E., Pacaud, L., Patel, N., Harrison, S. J., & Einsele, H.
- Affiliations
- From the Cancer Center Clínica Universidad de Navarra, Centro Investigación Medica Aplicada, Instituto de Investigación de Navarra, Centro Investigación Biomédica en Red Cáncer (CIBERONC), Pamplona (J.S.-M.), the University Hospital of Salamanca, Instituto de Investigación Biomédica de Salamanca, Centro Investigación del Cáncer, CIBERONC, Salamanca (M.-V.M.), the Amyloidosis and Myeloma Unit, Department of Hematology, Hospital Clínic of Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona (C.F.L.), the Hematological Malignancies Clinical Research Unit, Hospital 12 de Octubre Universidad Complutense, Centro Nacional de Investigaciones Oncológicas, CIBERONC, Madrid (J.M.-L.), and the Institut Català d’Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Badalona (A.O.) — all in Spain; the Medical College of Wisconsin, Milwaukee (B.D.); the University College London Cancer Institute (K.Y.) and University College London Hospitals, NHS Foundat...
- Medical College of Wisconsin (US)
- Inserm (FR)
- University Medical Center Groningen (NL)
- Poznan University of Medical Sciences (PL)
- University College London Hospitals NHS Foundation Trust (GB)
- The University of Sydney (AU)
- The Royal Melbourne Hospital (AU)
- ORCID
- Dhakal, Binod
- Yong, Kwee
- Spencer, Andrew
- Anguille, Sébastien
- Mateos, María-Victoria
- Moreau, Philippe
- Touzeau, Cyrille
- Leleu, Xavier
- Avivi, Irit
- Ishida, Tadao
- Kim, Seok Jin
- Roeloffzen, Wilfried
- Dytfeld, Dominik
- Sidana, Surbhi
- Costa, Luciano J.
- Oriol, Albert
- Popat, Rakesh
- Khan, Abdullah M.
- Ho, P. Joy
- Lendvai, Nikoletta
- Schecter, Jordan M.
- Jackson, Carolyn C.
- Li, Katherine
- Chen, Diana
- Nagle, Sarah
- Pacaud, Lida
- Patel, Nitin
- Harrison, Simon J.
- Einsele, Hermann
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-07-27
- Volume
- 389
- Issue
- 4
- Pages
- 335-347
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4379375986
- Semantic Scholar
- e537b398daa738a9f57ecb0da894878f49df8dae
- Cited by
- 827
- References
- 27
- Citations by year
- 2026: 257 · 2025: 279 · 2024: 230 · 2023: 60
- FWCI
- 169.95
- Type
- journal article
- Language
- en
- Open access
- green
- research.rug.nl
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion, other-oa)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, other-oa)
- UCL Discovery (University College London) (submittedVersion)
- Minerva Access (University of Melbourne) (submittedVersion)
- Funders
- Janssen Research & Development, LLC
- Legend Biotech USA Inc.
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- cilta-cel, ciltacabtagene autoleucel, lenalidomide-refractory multiple myeloma, progression-free survival, standard of care comparison, cytokine release syndrome, neurotoxicity, non-relapse mortality, minimal residual disease, relapsed/refractory multiple myeloma, adverse events
- MeSH terms
- Antineoplastic Agents, Immunological, Lenalidomide, Progression-Free Survival, Humans, Multiple Myeloma, Immunotherapy, Adoptive, Drug Resistance, Neoplasm, Neurotoxicity Syndromes, B-Cell Maturation Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-12, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-12 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.